Rezonic casopitant regulatory update

GlaxoSmithKline submitted an NDA for IV and oral formulations of Rezonic casopitant as an adjunct to prevent chemotherapy-induced nausea and vomiting (CINV) and to prevent postoperative nausea and vom...